---

Studying atherogenic index of plasma and lipoprotein (A) for better cardiac risk stratification in public health

---

Original Article

Author Details : M Vasanthan, Birundha S, Shenbaga Lalitha.S*, Rajalakshmi K, Balasubramanian A

Volume : 7, Issue : 1, Year : 2020

Article Page : 76-79

https://doi.org/10.18231/j.ijcbr.2020.016

Suggest article by email

Get Permission

---

Abstract

Aim: The aim of the study is to correlate Atherogenic Index of Plasma fAIP = log (TGL/HDL)g and with
Lipoprotein(a) concentrations in diabetic patients compared to healthy subjects.
Materials and Methods: The study included 30 non-diabetic subjects and 30 diabetic patients.
Lipoprotein(a) [Lp (a)] was estimated by Immunoturbidimetry and the parameters Triglyceride and High
Density Lipoprotein (HDL) by their respective methods in Biochemistry Auto-analyzer.
Results: It was found that, there is a positive correlation of Lp(a) with the AIP.
Conclusion: It is summarized that, the lipoprotein ratio like AIP shall be accepted as a better indicator
of cardio-vascular risk other than taking into account one of the lipoproteins as such. Estimating
Lipoprotein(a) is costlier compared to the other lipoproteins, which makes it an objectionable parameter
by the patients themselves. In the future, we would thereby, insist the rationale behind estimating the
lipoprotein ratios as better markers of assessing cardio-vascular risks.

Keywords: High Density Lipoprotein (HDL), Atherogenic Index of Plasma (AIP), Lipoprotein(a) (Lp(a))

How to cite : Vasanthan M, Birundha S, Lalitha.s S, Rajalakshmi K, Balasubramanian A, Studying atherogenic index of plasma and lipoprotein (A) for better cardiac risk stratification in public health. Int J Clin Biochem Res 2020;7(1):76-79

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.